DexCom Aktie
WKN: A0D9T1 / ISIN: US2521311074
29.08.2006 11:00:00
|
DexCom Receives FDA Approval for DM(TM) Consumer Data Manager; Software for Patients to Download Data From STS(TM) Continuous Glucose Monitoring System
"We are very pleased to begin providing the DexCom DM ConsumerData Manager, as this was one of top requests from our customers foradditional features for the STS Continuous Glucose Monitoring System.The software was designed to be easy to use and we are hopeful thesoftware will help patients gain better insight into their diabetes,"said Tae Andrews, DexCom's Vice President of Marketing. "We arecommitted to providing leadership in the continuous glucose monitoringcategory and to continued improvement of our STS platform. Since thelaunch of our STS Continuous Glucose Monitoring System in March 2006,we have introduced Health Care Professional Patient Manager softwareand filed a PMA-Supplement with the FDA for our second generation7-day STS Continuous Glucose Monitoring System."
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, isdeveloping and marketing continuous glucose monitoring systems forpeople with diabetes.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operatinghistory. The company received approval from the FDA for its STScontinuous glucose monitor on March 24, 2006, and has only recentlylaunched the sale of this product throughout the United States.Successful commercialization of the company's products is subject tonumerous risks and uncertainties, including a lack of acceptance inthe marketplace by physicians and patients, the inability tomanufacture products in commercial quantities at an acceptable cost,possible delays in the company's development programs, the inabilityof patients to receive reimbursements from third-party payors andinadequate financial and other resources. Certain of these risks anduncertainties, in addition to other risks, are more fully described inthe company's quarterly report on Form 10-Q for the period ending June30, 2006, as filed with the Securities and Exchange Commission on July21, 2006.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DexCom Inc.mehr Nachrichten
22.04.25 |
Dienstagshandel in New York: NASDAQ 100 zum Ende des Dienstagshandels mit Kursplus (finanzen.at) | |
22.04.25 |
Optimismus in New York: NASDAQ 100 am Nachmittag stärker (finanzen.at) | |
22.04.25 |
Börse New York in Grün: NASDAQ 100 steigt mittags (finanzen.at) | |
22.04.25 |
NASDAQ Composite Index-Titel DexCom-Aktie: So viel hätten Anleger mit einem Investment in DexCom von vor einem Jahr verloren (finanzen.at) | |
17.04.25 |
Donnerstagshandel in New York: NASDAQ 100 zum Start in der Gewinnzone (finanzen.at) | |
16.04.25 |
Erste Schätzungen: DexCom öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
15.04.25 |
NASDAQ Composite Index-Wert DexCom-Aktie: So viel Gewinn hätte eine Investition in DexCom von vor 10 Jahren abgeworfen (finanzen.at) | |
11.04.25 |
Gute Stimmung in New York: NASDAQ 100 schlussendlich freundlich (finanzen.at) |
Analysen zu DexCom Inc.mehr Analysen
Aktien in diesem Artikel
DexCom Inc. | 62,89 | 7,34% |
|
Indizes in diesem Artikel
NASDAQ Comp. | 17 382,94 | 1,26% |